McKesson Corporation (MCK) Covered Calls

McKesson Corporation covered calls McKesson Corporation is a global leader in healthcare supply chain management and pharmaceutical distribution. As one of the largest distributors in North America, it plays a vital role in delivering one-third of all medications used daily in the U.S. The company operates through segments including North American Pharmaceutical, Oncology and Multispecialty, and Prescription Technology Solutions, focusing on specialty care and tech-enabled services for providers and manufacturers.

You can sell covered calls on McKesson Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MCK (prices last updated Thu 4:16 PM ET):

McKesson Corporation (MCK) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
916.00 -37.19 890.00 969.00 1.5M - 117
Covered Calls For McKesson Corporation (MCK)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 915 15.70 953.30 -4.0% -162.2%
Mar 20 920 27.00 942.00 -2.2% -21.7%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

McKesson Corporation (MCK) is a global healthcare giant that serves as the backbone of the North American pharmaceutical supply chain. With its 2026 exit from the European market officially complete, the company has pivoted its capital and focus toward high-growth, high-margin verticals. McKesson excels at the complex logistics of drug distribution while increasingly providing the technology and clinical support necessary to manage the specialized therapies of the future.

Core Business and Products

  1. North American Pharmaceutical: This core engine handles the wholesale distribution of branded, generic, and specialty pharmaceuticals across the U.S. and Canada. It serves a diverse customer base, from large retail national accounts to independent pharmacies and health systems.
  2. Oncology and Multispecialty: This segment is a primary growth pillar, anchored by The US Oncology Network. Following the 2025 and early 2026 acquisitions of PRISM Vision Group and Core Ventures, McKesson has expanded its reach beyond cancer care into retinal and ophthalmic specialties, offering practice management and specialized drug distribution.
  3. Prescription Technology Solutions (RxTS): A high-margin technology business that helps patients access and afford their medications. This segment provides digital tools for prior authorization, real-time prescription benefit checks, and third-party logistics (3PL) services for biopharma manufacturers.
  4. Medical-Surgical Solutions: This segment distributes medical supplies and equipment to non-acute care settings, such as physician offices and surgery centers. Notably, McKesson announced its intent in 2025 to separate this segment into an independent company to further sharpen its enterprise focus.

Competitive Landscape

McKesson operates in a highly consolidated industry known for razor-thin margins and massive scale. Its primary rivals are the other members of the "Big Three" distributors: Cencora and Cardinal Health. In the medical-surgical and specialized distribution space, it contends with Henry Schein and Medline Industries. For technology and patient access solutions, the company competes with vertically integrated giants like CVS Health and specialized fintech players in the healthcare arena.

Strategic Outlook and Innovation

In 2026, McKesson is defining itself through "Digital Modernization" and "Specialty Expansion." The company is aggressively implementing AI-powered operations to enhance supply chain predictability and staff productivity, particularly in its automated distribution centers. A major strategic shift this year is the finalization of its European divestiture, allowing for more disciplined capital deployment toward its oncology ecosystem and biopharma services. Innovation is centered on "Agentic AI" for digitizing enrollment workflows for specialty medications and accelerating patient access to life-saving therapies. Management remains committed to a balanced capital allocation strategy, which includes steady dividend growth and significant share repurchases. By focusing on the "Specialty Era" of medicine—characterized by cell and gene therapies—McKesson aims to maintain its leadership position while driving operational efficiencies through its modernized global infrastructure.